Education
About Us
Working with TipRanks
Follow Us
Evoke Pharma (EVOK)
NASDAQ:EVOK
EVOK Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.94 - $12.32
Previous CloseN/A
Volume6.47K
Average Volume (3M)4.88M
Market Cap
$8.17M
Enterprise Value-$470.37K
Total Cash (Recent Filing)$12.62M
Total Debt (Recent Filing)$144.84K
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Nov 05, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,492,858
10 Day Avg. Volume149,849
30 Day Avg. Volume4,884,307
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.06
Enterprise Value/Revenue-0.04
Enterprise Value/Gross Profit-0.04
Enterprise Value/Ebitda0.10
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Evoke Pharma News
EVOK FAQ
What was Evoke Pharma’s price range in the past 12 months?
Evoke Pharma lowest stock price was $1.94 and its highest was $12.32 in the past 12 months.
What is Evoke Pharma’s market cap?
Evoke Pharma’s market cap is $8.17M.
When is Evoke Pharma’s upcoming earnings report date?
Evoke Pharma’s upcoming earnings report date is Nov 05, 2025 which is in 84 days.
How were Evoke Pharma’s earnings last quarter?
Currently, no data Available
Is Evoke Pharma overvalued?
According to Wall Street analysts Evoke Pharma’s price is currently Overvalued.
Does Evoke Pharma pay dividends?
Evoke Pharma does not currently pay dividends.
What is Evoke Pharma’s EPS estimate?
Evoke Pharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evoke Pharma have?
Evoke Pharma has 1,492,858 shares outstanding.
What happened to Evoke Pharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evoke Pharma?
Currently, no hedge funds are holding shares in EVOK
Company Description
Evoke Pharma
Evoke Pharma (EVOK) is a specialty pharmaceutical company focused on the development and commercialization of drugs primarily for the treatment of gastrointestinal (GI) disorders. The company's flagship product is Gimoti, a nasal spray formulation of metoclopramide, designed to relieve symptoms of acute and recurrent diabetic gastroparesis in adult women. Evoke Pharma operates within the biopharmaceutical sector, with an emphasis on addressing unmet medical needs in the GI space.
Technical Analysis
Ownership Overview
53.21% Insiders
0.82% Mutual Funds
14.53% Other Institutional Investors
31.27% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---